Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Site-specific modifications of light chain glycosylated antilymphoma (LL2) and anti-carcinoembryonic antigen (hImmu-14-N) antibody divalent f1agments.

Govindan SV, Goldenberg DM, Griffiths GL, Leung SO, Losman MJ, Hansen HJ.

Cancer Res. 1995 Dec 1;55(23 Suppl):5721s-5725s.

2.

Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.

Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, Hansen HJ, Goldenberg DM.

Bioconjug Chem. 2002 Sep-Oct;13(5):1054-70.

PMID:
12236788
3.

Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments.

Leung S, Losman MJ, Govindan SV, Griffiths GL, Goldenberg DM, Hansen HJ.

J Immunol. 1995 Jun 1;154(11):5919-26.

PMID:
7751635
4.
5.

The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments.

Leung SO, Qu Z, Hansen HJ, Shih LB, Wang J, Losman MJ, Goldenberg DM, Sharkey RM.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3106s-3117s.

PMID:
10541351
8.

Biodistribution of anti-CEA F(ab')2 fragments conjugated with chelating polymers: influence of conjugate electron charge on tumor uptake and blood clearance.

Slinkin MA, Curtet C, Faivre-Chauvet A, Sai-Maurel C, Gestin JF, Torchilin VP, Chatal JF.

Nucl Med Biol. 1993 May;20(4):443-52.

PMID:
8504286
9.

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.

Casey JL, King DJ, Chaplin LC, Haines AM, Pedley RB, Mountain A, Yarranton GT, Begent RH.

Br J Cancer. 1996 Nov;74(9):1397-405.

10.

Introduction of five potentially metabolizable linking groups between 111In-cyclohexyl EDTA derivatives and F(ab')2 fragments of anti-carcinoembryonic antigen antibody--I. A new reproducible synthetic method.

Gestin JF, Faivre-Chauvet A, Mease RC, Sai-Maurel C, Thédrez P, Slinkin M, Meinken GE, Srivastava SC, Chatal JF.

Nucl Med Biol. 1993 Aug;20(6):755-62.

PMID:
8401376
11.

Site-specific conjugation of an enzyme and an antibody fragment.

Werlen RC, Lankinen M, Rose K, Blakey D, Shuttleworth H, Melton R, Offord RE.

Bioconjug Chem. 1994 Sep-Oct;5(5):411-7.

PMID:
7849070
12.
13.

A cross-linked monoclonal antibody fragment for improved tumor targeting.

Stalteri MA, Mather SJ.

Bioconjug Chem. 1995 Mar-Apr;6(2):179-86.

PMID:
7599261
14.

Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.

Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, Cheung NK, Larson SM.

Nucl Med Biol. 1996 Jan;23(1):1-8.

PMID:
9004907
15.

Evaluation of a direct method for technetium labeling intact and F(ab')2 1A3, an anticolorectal monoclonal antibody.

Schwarz SW, Connett JM, Anderson CJ, Rocque PA, Philpott GW, Guo LW, Welch MJ.

Nucl Med Biol. 1994 May;21(4):619-26.

PMID:
9234319
16.

A comparison of cleavable and noncleavable hydrazinopyridine linkers for the 99mTc labeling of Fab' monoclonal antibody fragments.

Bridger GJ, Abrams MJ, Padmanabhan S, Gaul F, Larsen S, Henson GW, Schwartz DA, Longley CB, Burton CA, Ultee ME.

Bioconjug Chem. 1996 Mar-Apr;7(2):255-64.

PMID:
8983348
17.
18.

Improved radioimaging and tumor localization with monoclonal F(ab')2.

Wahl RL, Parker CW, Philpott GW.

J Nucl Med. 1983 Apr;24(4):316-25.

19.

The in vitro and in vivo anti-tumour activity of N-AcMEL-(Fab')2 conjugates.

Smyth MJ, Pietersz GA, McKenzie IF.

Br J Cancer. 1987 Jan;55(1):7-11.

20.

The labeling of high affinity sites of antibodies with 99mTc.

Paik CH, Phan LN, Hong JJ, Sahami MS, Heald SC, Reba RC, Steigman J, Eckelman WC.

Int J Nucl Med Biol. 1985;12(1):3-8.

PMID:
2989197
Items per page

Supplemental Content

Write to the Help Desk